Lantern Pharma LTRN Insider Ownership

Updated Oct 10, 2026

Across the past 12 months, open-market trades by Lantern Pharma insiders were all purchases, totaling $100,001 (48.54K shares).

• Among LTRN's insiders, D. Jeffrey Keyser (Director) was the top open-market buyer in the past 12 months, with $100,001 of stock purchased (48.54K shares) and the latest purchase on May 12, 2026.
• Per Business Quant, LTRN insiders together hold 1.22Mn shares based on their latest Form 4 filings, unchanged from 1.22Mn shares at the end of Q2 2026 and up 13.28% from 1.08Mn shares at the end of Q3 2025.
• By type of ownership, LTRN insiders hold 11.72% of their shares directly (142.85K shares) and 88.28% indirectly (1.08Mn shares).
• Per Business Quant, 3 insiders of LTRN hold shares, counting officers, directors and 10% owners who have filed a Form 4 in the past two years.
• Lantern Pharma's three biggest insider holders are Aaron G.L. Fletcher (10% owner, 1.08Mn shares), D. Jeffrey Keyser (Director, 94.3K shares) and Lee Troy Schalop (Director, 48.54K shares), based on their latest Form 4 filings.
• Aaron G.L. Fletcher holds 88.28% of the combined insider position in Lantern Pharma.
• Institutions accounted for 22.59% of LTRN's outstanding shares in Q2 2026, insiders about 9.55% per their latest Form 4 filings, and other investors, including the public, about 67.86%.
• In the past year, 7 insiders of Lantern Pharma submitted 9 Form 4 filings reporting trades, awards or other transactions.
• Insider figures for LTRN include Form 4 filings through May 14, 2026.